What Medical Device RA Actually Does in South Korea — One Year in the Regulatory Cycle

Key takeaway — RA (Regulatory Affairs) is the title a company gives the role; the position the Medical Devices Act names is the quality manager. A person seeking a manufacturing business licence must appoint one (Article 6(7)), and the requirement applies to importers by reference (Article 15(6)). An RA year turns on a cycle of approval → change → renewal → post-market work, and within it sit fixed deadlines on monthly, annual, three-year, and five-year rhythms. The moment a company starts to need RA is "when the number of items grows and expiry dates begin to scatter across different days." What separates hiring in-house from placing work outside is not budget but how often the work recurs. This guide is set out against the statutes in force as of August 2026.

RA is the name a company gives; quality manager is the position the law names

Job postings say "RA specialist," the office calls it "the regulatory person," and the business card reads "Regulatory Affairs." Yet nowhere in the Medical Devices Act does the title RA appear. The Act points to exactly one position — the quality manager.

Article 6(7) of the Medical Devices Act requires a person seeking a manufacturing business licence to appoint a quality manager, as prescribed by Ordinance of the Prime Minister, to carry out the duties set out in Article 6-2(1). Those duties cover guidance and supervision of employees engaged in manufacturing, manufacturing and quality control, and safety management, including safety management for adverse events after marketing. The same obligation reaches importers through the reference provision in Article 15(6). Assuming it does not apply because you only import is a common mistake in practice, and it is wrong.

There is also a point where the two names meet institutionally. Article 11 of the Enforcement Rule lists the qualification requirements for a quality manager across several subparagraphs, and among them is a person holding the medical device RA (Regulatory Affairs) specialist qualification accredited by the Minister of Food and Drug Safety under Article 19(1) of the Framework Act on Qualifications. It sits alongside items such as biomedical engineer and quality management engineer certifications, a bachelor's degree or higher in natural sciences, engineering, or medicine, and a set period of quality control experience.

Put simply: RA is the name of the function, and the quality manager is the part of that function for which the law requires a named individual. The working scope of an actual RA specialist is broader than the quality manager's statutory duties, typically running from drafting approval dossiers through to reviewing advertising copy.

An RA year — approval, change, renewal, post-market

Because the role is called "regulatory affairs," it is easy to assume the work ends when the certificate arrives. The actual distribution of hours is closer to the opposite. Approval is a project measured in months; everything else is a deadline that keeps coming back.

Cycle	Work	Basis
Monthly	Supply reporting — by the end of the month following the month of supply	Act Article 31-2 · Enforcement Rule Article 54-2
As arising	Change approval, change certification, change notification; reporting of minor changes	Act Article 12
As arising	Reporting and record-keeping on adverse events; recalls and other measures	Act Article 31
As arising	Filing for self-regulatory advertising review; labelling review	Act Article 25 · Articles 20–23
Annually	At least eight hours of quality manager training	Enforcement Rule Article 13
Every 3 years	KGMP periodic audit (exemptions apply)	Regulations on Medical Device Manufacturing and Quality Control, Article 4
Every 5 years	Renewal of manufacturing approval — apply at least 180 days before expiry	Act Article 49 · Enforcement Rule Article 62-2

① Approval — the starting point. This is where item classification fixes the class, the class determines whether the route is notification, certification, or approval, and the technical documentation and test reports are assembled to match. It is project work, and one person can be occupied with it for months.

② Change — the axis most often missed. Article 12 of the Act requires a change approval, change certification, or change notification where approved, certified, or notified particulars change. A manufacturer switching a component supplier or adjusting packaging specifications happens inside sales and procurement, and RA tends to find out afterwards — which is how unreported changes quietly accumulate. Which changes are subject to review and which are covered by a minor change report is dealt with in the change approval and change notification guide.

③ Renewal — the deadline that comes round every five years. Article 49 of the Act sets the validity period of a manufacturing approval at five years from the date approval or certification is granted, or the notification accepted (exemptions for export goods, conditional approvals, and similar are in Article 62 of the Enforcement Rule). The renewal application is due at least 180 days before the expiry date, and is filed with the original certificate together with materials demonstrating that safety and efficacy have been maintained over the preceding validity period, and production or import performance data (Enforcement Rule Article 62-2). This is where the practical trap sits — renewal materials are not produced at renewal time; they are accumulated over five years. A company that has not kept performance and safety information tidy along the way ends up reconstructing five years of it six months before expiry.

If you operate a manufacturing site, periodic audits for KGMP conformity run on their own schedule. Article 4 of the Regulations on Medical Device Manufacturing and Quality Control provides for initial, additional, change, and periodic audits, with periodic audits typically operated on a three-year cycle. Class 1 devices are subject to exemptions under the same notice, so it varies by item — see the KGMP certification guide for detail.

④ Post-market — the work that returns every month. Post-market management is not one task but a bundle. Supplies to medical institutions and to other sellers or rental businesses must be reported monthly, by the end of the month following supply (Act Article 31-2; Enforcement Rule Article 54-2); the UDI standard code is marked on the container or outer casing and product information registered in the Integrated Medical Device Information System (Act Article 20, subparagraph 8; Article 31-3). Deaths and serious adverse events must be reported immediately with records maintained, and where quality defects cause harm, recalls and other necessary measures follow (Act Article 31). If you advertise, self-regulatory review (Act Article 25) belongs on this axis too. The practical monthly routine is set out in the UDI and supply reporting guide, and the boundaries of advertising language in the medical device advertising rules guide.

There is one more duty that falls on the individual. A quality manager must complete at least eight hours of training each year, and must complete it within six months of starting work (except where they finished that year's training before starting). That is prescribed by Article 13 of the Enforcement Rule.

When a company starts to need RA

A company that starts with a single item gets by with the founder or a salesperson doubling up. At some point it stops working — and the turning point comes not from revenue but from the number of things being managed and the spread of their expiry dates. When two or three of the following start to overlap, it is time to build a structure.

• More than three items — different approval dates mean renewal deadlines scatter. This is where management by a single spreadsheet breaks down.
• Moving from Class 1 up to Class 2 or above — technical documentation review attaches, and judging whether a change requires review gets considerably harder.
• Switching from importing to manufacturing, or adding a site — every manufacturing site needs its own quality manager, and KGMP periodic audit dates are added.
• Deliveries to hospitals or wholesalers begin — the moment business-to-business supply exists, supply reporting becomes a live obligation.
• Advertising starts in earnest — someone has to check each phrase against the approved intended use and whether review is required.
• The first renewal deadline is two years out — unless performance and safety data start accumulating now, it becomes a reconstruction job just before expiry.

Hire or outsource — what actually decides it

One premise has to be settled first. The quality manager position is not something you outsource. Article 11 of the Enforcement Rule requires a person seeking a manufacturing business licence to appoint at least one quality manager per manufacturing site and sets qualification requirements separately. What an outside consultancy can take on is the execution of individual tasks such as approval, change, and renewal work — not the position that requires a named person. So the realistic question is not the binary of hiring versus outsourcing, but which work sits inside and which sits outside.

Three axes separate them.

Axis	Belongs inside	Belongs outside
Recurrence	Work that repeats monthly or annually — supply reporting, training, record-keeping	Work that arises once every few years — a new approval, an initial KGMP audit, a first renewal
Access to internal data	Work that needs production, shipment, and transaction records	Work centred on statutory interpretation and dossier structure
Turnover of experience	Work where accumulated knowledge of your own product helps	Work where one or two instances a year never builds instinct — responding to review deficiencies, judging class boundaries

The third axis carries the most weight in practice. If an in-house specialist handles a new approval once every two years, they start each time in a state not far from doing it for the first time. Conversely, monthly supply reporting requires access to internal transaction data, so placing it outside multiplies the round trips of sending files back and forth. Put each on the wrong side and both become inefficient.

The cost comparison for a single project — putting the statutory fee and the agency fee in the same table — is treated separately in Class 1 notification: do it yourself or hire an agency? The question in this guide sits one level above that: how to structure the function.

What CLARE Partners does

Rather than replacing the RA function wholesale, CLARE Partners scopes the engagement by first splitting what belongs inside from what belongs outside, and then taking on only the part placed outside.

• Post-market surveillance outsourcing (monthly) — UDI, change management, and periodic reporting bundled together, from KRW 800,000 per month for Class 1 (Class 2 from KRW 1.7 million; Class 3–4 from KRW 3.5 million)
• Supply reporting (monthly) — the monthly reporting duty taken on its own, from KRW 500,000 per month
• Class 1 notification from KRW 2 million · Class 2 certification from KRW 6 million (statutory fees itemised separately in the quotation)
• Labelling review from KRW 500,000 · Advance advertising review — preparing the review application and handling the response
• Free pre-review — send us your item list and approval dates and we will come back within one business day with a first read on your expiry and obligation status

The full fee schedule by item and how quotations are structured are set out under regulatory consulting services.

---

The difficulty of RA work lies not in its complexity but in deadlines on different cycles running at the same time. Once a month, once a year, once every three years, once every five — each scattered across different dates, and missing any one of them means reconstructing it retroactively. Send us just the approval dates and validity periods of the items you currently hold through a free pre-review, and we will start by pinpointing which deadline comes round first.

As of August 2026. Legal basis: Medical Devices Act of Korea (Act No. 21263, in force 1 Jul 2026) Article 6 (Licensing of Manufacturing Business), paragraph 7 · Article 6-2 (Matters to Be Observed by Quality Managers) · Article 12 (Change Approval) · Article 15 (Licensing of Import Business), paragraph 6 · Article 25 (Self-Regulatory Review of Advertising) · Article 31 (Management of Adverse Events) · Article 31-2 (Reporting of Medical Device Supply Details) · Article 31-3 (Establishment of the Integrated Medical Device Information System) · Article 49 (Renewal of Manufacturing Approval); Enforcement Rule of the Medical Devices Act (Ordinance of the Prime Minister No. 2127, in force 1 Jul 2026) Article 11 (Qualifications of Quality Managers) · Article 13 (Content and Hours of Quality Manager Training) · Article 54-2 (Reporting of Medical Device Supply Details) · Article 62 (Devices Exempt from the Validity Period) and Article 62-2 (Renewal of Manufacturing Approval) · Regulations on Medical Device Manufacturing and Quality Control (MFDS Notice), Article 4 — based on the official texts at the Korean Law Information Center; contents may change when the statutes are amended. The periodic audit cycle reflects the published guidance of designated audit bodies.